AbbVie Inc. Stock price

Equities

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX 11:01:33 2024-03-28 am EDT 5-day change 1st Jan Change
181.2 USD +0.45% Intraday chart for AbbVie Inc. +1.94% +16.76%
Sales 2024 * 54.54B Sales 2025 * 57.81B Capitalization 319B
Net income 2024 * 9.36B Net income 2025 * 11.12B EV / Sales 2024 * 6.79 x
Net Debt 2024 * 50.81B Net Debt 2025 * 42.29B EV / Sales 2025 * 6.26 x
P/E ratio 2024 *
33.6 x
P/E ratio 2025 *
27.3 x
Employees 50,000
Yield 2024 *
3.45%
Yield 2025 *
3.61%
Free-Float 96.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.42%
1 week+1.94%
Current month+2.78%
1 month+1.65%
3 months+16.92%
6 months+18.84%
Current year+16.76%
More quotes
1 week
176.78
Extreme 176.78
181.38
1 month
175.39
Extreme 175.39
182.89
Current year
154.77
Extreme 154.7704
182.89
1 year
130.96
Extreme 130.9601
182.89
3 years
104.17
Extreme 104.17
182.89
5 years
62.55
Extreme 62.55
182.89
10 years
45.45
Extreme 45.45
182.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 12-12-31
Director of Finance/CFO 57 12-12-31
President 53 11-12-31
Members of the board TitleAgeSince
Director/Board Member 63 12-12-31
Director/Board Member 66 12-12-31
Director/Board Member 70 12-12-31
More insiders
Date Price Change Volume
24-03-28 181 +0.37% 602 761
24-03-27 180.4 +0.65% 5,073,508
24-03-26 179.2 +0.37% 4,392,427
24-03-25 178.5 +0.04% 4,366,502
24-03-22 178.4 +0.54% 4,084,352

Delayed Quote Nyse, March 28, 2024 at 10:46 am EDT

More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
180.4 USD
Average target price
183.9 USD
Spread / Average Target
+1.96%
Consensus
  1. Stock
  2. Equities
  3. Stock AbbVie Inc. - Nyse